The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE:ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .
This approval is supported by efficacy and safety data from the Phase 3 SELECT-AXIS 2 clinical trial (Study 1) and the Phase 2/3 SELECT-AXIS 1 clinical trial evaluating RINVOQ.
In both SELECT-AXIS 1 and SELECT-AXIS 2 clinical trials, RINVOQ 15 mg met primary endpoint of achieving an ASAS40* response compared to those receiving placebo at week 14.
Thomas Hudson, M.D., chief scientific officer, stated, "Ankylosing spondylitis is a debilitating disease that often affects younger adults and, over time, can result in lasting structural damage that can take an emotional toll on a patient's life, This latest approval demonstrates another important step forward in our mission to advance the standards of care in rheumatic diseases.”
Ankylosing Spondylitis (AS) is a chronic inflammatory musculoskeletal disease primarily affecting the spine and characterized by debilitating symptoms of inflammatory back pain, stiffness and restricted mobility.
Abbvie is currently trading down 7.4 percent at $145.
